{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:08:58Z","timestamp":1780708138221,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"SarcoidosisUK"},{"name":"Nanostring"},{"name":"Myriad-RBM"},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT104726"],"award-info":[{"award-number":["WT104726"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>In sarcoidosis granulomas, monocyte-derived macrophages are activated by pro-inflammatory cytokines including TNF and IL-6. Current drug treatment for sarcoidosis aims to suppress inflammation but disabling side effects can ensue. The macrolide azithromycin may be anti-inflammatory. We aimed to determine whether treatment with azithromycin affects blood inflammatory gene expression and monocyte functions in sarcoidosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Blood samples were collected from patients with chronic pulmonary sarcoidosis enrolled in a single arm, open label clinical trial who received oral azithromycin 250 mg once daily for 3 months. Whole blood inflammatory gene expression with or without LPS stimulation was measured using a 770-mRNA panel. Phenotypic analysis and cytokine production were conducted by flow cytometry and ELISA after 24h stimulation with growth factors and TLR ligands. mTOR activity was assessed by measuring phosphorylated S6RP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Differential gene expression analysis indicated a state of heightened myeloid cell activation in sarcoidosis. Compared with controls, sarcoidosis patients showed increased LPS responses for several cytokines and chemokines. Treatment with azithromycin had minimal effect on blood gene expression overall, but supervised clustering analysis identified several chemokine genes that were upregulated. At the protein level, azithromycin treatment increased LPS-stimulated TNF and unstimulated IL-8 production. No other cytokines showed significant changes following azithromycin. Blood neutrophil counts fell during azithromycin treatment whereas mononuclear cells remained stable. Azithromycin had no detectable effects on mTOR activity or activation markers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Blood myeloid cells are activated in sarcoidosis, but azithromycin therapy did not suppress inflammatory gene expression or cytokine production in blood.<\/jats:p>\n                <jats:p>Trial registration: EudraCT 2019-000580-24 (17 May 2019)<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00408-024-00743-w","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T16:02:33Z","timestamp":1726502553000},"page":"683-693","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effects of Azithromycin on Blood Inflammatory Gene Expression and Cytokine Production in Sarcoidosis"],"prefix":"10.1007","volume":"202","clinical-trial-number":[{"clinical-trial-number":"2019-000580-24","registry":"10.18810\/euctr"}],"author":[{"given":"Simon D.","family":"Fraser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susannah","family":"Thackray-Nocera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Flockton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally R.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Crooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon P.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"issue":"8","key":"743_CR1","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1513\/AnnalsATS.201511-760OC","volume":"13","author":"RP Baughman","year":"2016","unstructured":"Baughman RP, Field S, Costabel U, Crystal RG, Culver DA, Drent M et al (2016) Sarcoidosis in America. analysis based on health care use. Ann Am Thorac Soc 13(8):1244\u20131252","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"743_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/thoraxjnl-2019-214348","volume":"76","author":"M Thillai","year":"2021","unstructured":"Thillai M, Atkins CP, Crawshaw A, Hart SP, Ho LP, Kouranos V et al (2021) BTS clinical statement on pulmonary sarcoidosis. Thorax 76(1):4\u201320. https:\/\/doi.org\/10.1136\/thoraxjnl-2019-214348","journal-title":"Thorax"},{"key":"743_CR3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04079-2020","author":"PB Robert","year":"2021","unstructured":"Robert PB, Dominique V, Peter K, Alexander GM, Wim AW, Athol W et al (2021) ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.04079-2020","journal-title":"Eur Respir J"},{"issue":"6","key":"743_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2165\/00063030-200317060-00005","volume":"17","author":"RP Baughman","year":"2003","unstructured":"Baughman RP, Iannuzzi M (2003) Tumour necrosis factor in sarcoidosis and its potential for targeted therapy. BioDrugs 17(6):425\u2013431. https:\/\/doi.org\/10.2165\/00063030-200317060-00005","journal-title":"BioDrugs"},{"issue":"1","key":"743_CR5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1378\/chest.106.1.156","volume":"106","author":"K Sahashi","year":"1994","unstructured":"Sahashi K, Ina Y, Takada K, Sato T, Yamamoto M, Morishita M (1994) Significance of interleukin 6 in patients with sarcoidosis. Chest 106(1):156\u2013160. https:\/\/doi.org\/10.1378\/chest.106.1.156","journal-title":"Chest"},{"issue":"1","key":"743_CR6","first-page":"20","volume":"20","author":"JC Grutters","year":"2003","unstructured":"Grutters JC, Sato H, Pantelidis P, Ruven HJ, McGrath DS, Wells AU et al (2003) Analysis of IL6 and IL1A gene polymorphisms in UK and dutch patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 20(1):20\u201327","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"3","key":"743_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/ni.3655","volume":"18","author":"M Linke","year":"2017","unstructured":"Linke M, Pham HT, Katholnig K, Schnoller T, Miller A, Demel F et al (2017) Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat Immunol 18(3):293\u2013302. https:\/\/doi.org\/10.1038\/ni.3655","journal-title":"Nat Immunol"},{"key":"743_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2021.102095","volume":"71","author":"J Pollock","year":"2021","unstructured":"Pollock J, Chalmers JD (2021) The immunomodulatory effects of macrolide antibiotics in respiratory disease. Pulm Pharmacol Ther 71:102095. https:\/\/doi.org\/10.1016\/j.pupt.2021.102095","journal-title":"Pulm Pharmacol Ther"},{"issue":"6","key":"743_CR9","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1128\/aac.49.6.2372-2377.2005","volume":"49","author":"M Bosnar","year":"2005","unstructured":"Bosnar M, Kelneri\u0107 Z, Muni\u0107 V, Erakovi\u0107 V, Parnham MJ (2005) Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob Agents Chemother 49(6):2372\u20132377. https:\/\/doi.org\/10.1128\/aac.49.6.2372-2377.2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"743_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1179\/joc.1997.9.1.23","volume":"9","author":"A Fietta","year":"1997","unstructured":"Fietta A, Merlini C, Gialdroni GG (1997) Requirements for intracellular accumulation and release of clarithromycin and azithromycin by human phagocytes. J Chemother 9(1):23\u201331. https:\/\/doi.org\/10.1179\/joc.1997.9.1.23","journal-title":"J Chemother"},{"issue":"1","key":"743_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1128\/aac.40.1.75","volume":"40","author":"A Wildfeuer","year":"1996","unstructured":"Wildfeuer A, Laufen H, Zimmermann T (1996) Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions. Antimicrob Agents Chemother 40(1):75\u201379. https:\/\/doi.org\/10.1128\/aac.40.1.75","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"743_CR12","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.4049\/jimmunol.1801228","volume":"203","author":"D Haydar","year":"2019","unstructured":"Haydar D, Cory TJ, Birket SE, Murphy BS, Pennypacker KR, Sinai AP et al (2019) Azithromycin polarizes macrophages to an M2 phenotype via Inhibition of the STAT1 and NF-\u03baB signaling pathways. J Immunol 203(4):1021\u20131030. https:\/\/doi.org\/10.4049\/jimmunol.1801228","journal-title":"J Immunol"},{"key":"743_CR13","doi-asserted-by":"publisher","first-page":"7438","DOI":"10.1038\/srep07438","volume":"4","author":"F Ratzinger","year":"2014","unstructured":"Ratzinger F, Haslacher H, Poeppl W, Hoermann G, Kovarik JJ, Jutz S et al (2014) Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity. Sci Rep 4:7438. https:\/\/doi.org\/10.1038\/srep07438","journal-title":"Sci Rep"},{"issue":"4","key":"743_CR14","doi-asserted-by":"publisher","first-page":"00534","DOI":"10.1183\/23120541.00534-2020","volume":"6","author":"SD Fraser","year":"2020","unstructured":"Fraser SD, Thackray-Nocera S, Shepherd M, Flockton R, Wright C, Sheedy W et al (2020) Azithromycin for sarcoidosis cough: an open-label exploratory clinical trial. ERJ open research 6(4):00534\u201302020. https:\/\/doi.org\/10.1183\/23120541.00534-2020","journal-title":"ERJ open research"},{"issue":"10","key":"743_CR15","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1164\/rccm.201106-1143OC","volume":"184","author":"LL Koth","year":"2011","unstructured":"Koth LL, Solberg OD, Peng JC, Bhakta NR, Nguyen CP, Woodruff PG (2011) Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis. Am J Respir Crit Care Med 184(10):1153\u20131163","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"743_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070630","volume":"8","author":"CI Bloom","year":"2013","unstructured":"Bloom CI, Graham CM, Berry MP, Rozakeas F, Redford PS, Wang Y et al (2013) Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS ONE 8(8):e70630. https:\/\/doi.org\/10.1371\/journal.pone.0070630","journal-title":"PLoS ONE"},{"issue":"20","key":"743_CR17","doi-asserted-by":"publisher","first-page":"7853","DOI":"10.1073\/pnas.1121072109","volume":"109","author":"J Maertzdorf","year":"2012","unstructured":"Maertzdorf J, Weiner J 3rd, Mollenkopf HJ, Bauer T, Prasse A, Muller-Quernheim J et al (2012) Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci U S A 109(20):7853\u20137858","journal-title":"Proc Natl Acad Sci U S A"},{"key":"743_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.567342","volume":"11","author":"L Garman","year":"2020","unstructured":"Garman L, Pelikan RC, Rasmussen A, Lareau CA, Savoy KA, Deshmukh US et al (2020) Single cell transcriptomics implicate novel monocyte and T cell immune dysregulation in sarcoidosis. Front Immunol 11:567342. https:\/\/doi.org\/10.3389\/fimmu.2020.567342","journal-title":"Front Immunol"},{"key":"743_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.822094","volume":"9","author":"K Yoshioka","year":"2022","unstructured":"Yoshioka K, Sato H, Kawasaki T, Ishii D, Imamoto T, Abe M et al (2022) Transcriptome analysis of peripheral blood mononuclear cells in pulmonary sarcoidosis. Front Med (Lausanne) 9:822094. https:\/\/doi.org\/10.3389\/fmed.2022.822094","journal-title":"Front Med (Lausanne)"},{"key":"743_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.848759","volume":"13","author":"C Ascoli","year":"2022","unstructured":"Ascoli C, Schott CA, Huang Y, Turturice BA, Wang W, Ecanow N et al (2022) Altered transcription factor targeting is associated with differential peripheral blood mononuclear cell proportions in sarcoidosis. Front Immunol 13:848759. https:\/\/doi.org\/10.3389\/fimmu.2022.848759","journal-title":"Front Immunol"},{"issue":"10","key":"743_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0274381","volume":"17","author":"B Khassawneh","year":"2022","unstructured":"Khassawneh B, Zhu C, Barkes B, Vestal B, Shrock S, Gillespie M et al (2022) Autoantibody profile in sarcoidosis, analysis from the GRADS sarcoidosis cohort. PLoS ONE 17(10):e0274381. https:\/\/doi.org\/10.1371\/journal.pone.0274381","journal-title":"PLoS ONE"},{"issue":"5","key":"743_CR22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/thoraxjnl-2019-213929","volume":"75","author":"D Smith","year":"2020","unstructured":"Smith D, Du Rand I, Addy CL, Collyns T, Hart SP, Mitchelmore PJ et al (2020) British thoracic society guideline for the use of long-term macrolides in adults with respiratory disease. Thorax 75(5):370\u2013404. https:\/\/doi.org\/10.1136\/thoraxjnl-2019-213929","journal-title":"Thorax"},{"key":"743_CR23","doi-asserted-by":"publisher","first-page":"38689","DOI":"10.1038\/srep38689","volume":"6","author":"SD Fraser","year":"2016","unstructured":"Fraser SD, Sadofsky LR, Kaye PM, Hart SP (2016) Reduced expression of monocyte CD200R is associated with enhanced proinflammatory cytokine production in sarcoidosis. Sci Rep 6:38689. https:\/\/doi.org\/10.1038\/srep38689","journal-title":"Sci Rep"},{"issue":"5","key":"743_CR24","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/j.1476-5381.2011.01576.x","volume":"165","author":"M Vran\u010di\u0107","year":"2012","unstructured":"Vran\u010di\u0107 M, Banjanac M, Nuji\u0107 K, Bosnar M, Murati T, Muni\u0107 V et al (2012) Azithromycin distinctively modulates classical activation of human monocytes in vitro. Br J Pharmacol 165(5):1348\u20131360. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01576.x","journal-title":"Br J Pharmacol"},{"issue":"7","key":"743_CR25","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/infdis\/jiv157","volume":"212","author":"N Iwanaga","year":"2015","unstructured":"Iwanaga N, Nakamura S, Oshima K, Kajihara T, Takazono T, Miyazaki T et al (2015) Macrolides promote CCL2-mediated macrophage recruitment and clearance of nasopharyngeal pneumococcal colonization in mice. J Infect Dis 212(7):1150\u20131159. https:\/\/doi.org\/10.1093\/infdis\/jiv157","journal-title":"J Infect Dis"},{"key":"743_CR26","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.3389\/fimmu.2019.02759","volume":"10","author":"M Gschwandtner","year":"2019","unstructured":"Gschwandtner M, Derler R, Midwood KS (2019) More than just attractive: how CCL2 influences myeloid cell behavior beyond chemotaxis. Front Immunol 10:2759. https:\/\/doi.org\/10.3389\/fimmu.2019.02759","journal-title":"Front Immunol"},{"issue":"7","key":"743_CR27","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1128\/aac.05798-11","volume":"56","author":"A Spyridaki","year":"2012","unstructured":"Spyridaki A, Raftogiannis M, Antonopoulou A, Tsaganos T, Routsi C, Baziaka F et al (2012) Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. Antimicrob Agents Chemother 56(7):3819\u20133825. https:\/\/doi.org\/10.1128\/aac.05798-11","journal-title":"Antimicrob Agents Chemother"},{"key":"743_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(23)00412-5","author":"EJ Giamarellos-Bourboulis","year":"2024","unstructured":"Giamarellos-Bourboulis EJ, Siampanos A, Bolanou A, Doulou S, Kakavoulis N, Tsiakos K et al (2024) Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. https:\/\/doi.org\/10.1016\/s2213-2600(23)00412-5","journal-title":"Lancet Respir Med"},{"issue":"3","key":"743_CR29","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/s0014-2999(02)02042-3","volume":"450","author":"O Culi\u0107","year":"2002","unstructured":"Culi\u0107 O, Erakovi\u0107 V, Cepelak I, Barisi\u0107 K, Brajsa K, Ferenci\u0107 Z et al (2002) Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 450(3):277\u2013289. https:\/\/doi.org\/10.1016\/s0014-2999(02)02042-3","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"743_CR30","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/jac\/47.6.867","volume":"47","author":"A Kurdowska","year":"2001","unstructured":"Kurdowska A, Noble JM, Griffith DE (2001) The effect of azithromycin and clarithromycin on ex vivo interleukin-8 (IL-8) release from whole blood and IL-8 production by human alveolar macrophages. J Antimicrob Chemother 47(6):867\u2013870. https:\/\/doi.org\/10.1093\/jac\/47.6.867","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"743_CR31","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1128\/aac.37.9.1786","volume":"37","author":"J Tomazic","year":"1993","unstructured":"Tomazic J, Kotnik V, Wraber B (1993) In vivo administration of azithromycin affects lymphocyte activity in vitro. Antimicrob Agents Chemother 37(9):1786\u20131789. https:\/\/doi.org\/10.1128\/aac.37.9.1786","journal-title":"Antimicrob Agents Chemother"},{"key":"743_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10010099","author":"T Nagano","year":"2021","unstructured":"Nagano T, Yamaguchi T, Kajiyama S, Suzuki T, Matsushima Y, Yashima A et al (2021) Effect of azithromycin on proinflammatory cytokine production in gingival fibroblasts and the remodeling of periodontal tissue. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10010099","journal-title":"J Clin Med"},{"key":"743_CR33","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3389\/fimmu.2018.00302","volume":"9","author":"P Zimmermann","year":"2018","unstructured":"Zimmermann P, Ziesenitz VC, Curtis N, Ritz N (2018) The immunomodulatory effects of macrolides-a systematic review of the underlying mechanisms. Front Immunol 9:302. https:\/\/doi.org\/10.3389\/fimmu.2018.00302","journal-title":"Front Immunol"},{"issue":"23","key":"743_CR34","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1182\/blood.2022016926","volume":"140","author":"N Vallet","year":"2022","unstructured":"Vallet N, Le Grand S, Bondeelle L, Hoareau B, Corneau A, Bouteiller D et al (2022) Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation. Blood 140(23):2500\u20132513. https:\/\/doi.org\/10.1182\/blood.2022016926","journal-title":"Blood"},{"issue":"12","key":"743_CR35","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1164\/rccm.200402-200OC","volume":"170","author":"WC Tsai","year":"2004","unstructured":"Tsai WC, Rodriguez ML, Young KS, Deng JC, Thannickal VJ, Tateda K et al (2004) Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med 170(12):1331\u20131339. https:\/\/doi.org\/10.1164\/rccm.200402-200OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"743_CR36","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1128\/AAC.40.9.2039","volume":"40","author":"C Wenisch","year":"1996","unstructured":"Wenisch C, Parschalk B, Zedtwitz-Liebenstein K, Weihs A, el Menyawi I, Graninger W (1996) Effect of single oral dose of azithromycin, clarithromycin, and roxithromycin on polymorphonuclear leukocyte function assessed ex vivo by flow cytometry. Antimicrob Agents Chemother 40(9):2039\u20132042","journal-title":"Antimicrob Agents Chemother"},{"issue":"1\u20132","key":"743_CR37","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejphar.2005.05.023","volume":"517","author":"MJ Parnham","year":"2005","unstructured":"Parnham MJ, Culi\u0107 O, Erakovi\u0107 V, Muni\u0107 V, Popovi\u0107-Grle S, Barisi\u0107 K et al (2005) Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. Eur J Pharmacol 517(1\u20132):132\u2013143. https:\/\/doi.org\/10.1016\/j.ejphar.2005.05.023","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"743_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005806","volume":"4","author":"CM Ribeiro","year":"2009","unstructured":"Ribeiro CM, Hurd H, Wu Y, Martino ME, Jones L, Brighton B et al (2009) Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia. PLoS ONE 4(6):e5806. https:\/\/doi.org\/10.1371\/journal.pone.0005806","journal-title":"PLoS ONE"},{"issue":"1","key":"743_CR39","doi-asserted-by":"publisher","first-page":"14453","DOI":"10.1038\/s41598-023-41577-5","volume":"13","author":"Z Varenyiova","year":"2023","unstructured":"Varenyiova Z, Rojas-Hernandez LS, Spano J, Capek V, Rosenberg-Hasson Y, Holmes T et al (2023) Azithromycin promotes proliferation, and inhibits inflammation in nasal epithelial cells in primary ciliary dyskinesia. Sci Rep 13(1):14453. https:\/\/doi.org\/10.1038\/s41598-023-41577-5","journal-title":"Sci Rep"},{"issue":"9","key":"743_CR40","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1172\/JCI46095","volume":"121","author":"M Renna","year":"2011","unstructured":"Renna M, Schaffner C, Brown K, Shang S, Tamayo MH, Hegyi K et al (2011) Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Investig 121(9):3554\u20133563. https:\/\/doi.org\/10.1172\/JCI46095","journal-title":"J Clin Investig"},{"issue":"5","key":"743_CR41","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.chest.2020.12.027","volume":"159","author":"WP Drake","year":"2021","unstructured":"Drake WP, Culver DA, Baughman RP, Judson MA, Crouser ED, James WE et al (2021) Phase II investigation of the efficacy of antimycobacterial therapy in chronic pulmonary sarcoidosis. Chest 159(5):1902\u20131912. https:\/\/doi.org\/10.1016\/j.chest.2020.12.027","journal-title":"Chest"},{"issue":"1","key":"743_CR42","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1183\/09031936.00068310","volume":"37","author":"R Vos","year":"2011","unstructured":"Vos R, Vanaudenaerde BM, Verleden SE, Vleeschauwer SID, Willems-Widyastuti A, Raemdonck DEV et al (2011) A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 37(1):164\u2013172. https:\/\/doi.org\/10.1183\/09031936.00068310","journal-title":"Eur Respir J"},{"issue":"5","key":"743_CR43","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1136\/thoraxjnl-2014-205998","volume":"70","author":"PA Corris","year":"2015","unstructured":"Corris PA, Ryan VA, Small T, Lordan J, Fisher AJ, Meachery G et al (2015) A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation. Thorax 70(5):442\u2013450. https:\/\/doi.org\/10.1136\/thoraxjnl-2014-205998","journal-title":"Thorax"},{"issue":"1","key":"743_CR44","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1128\/aac.02067-13","volume":"58","author":"H Li","year":"2014","unstructured":"Li H, Liu DH, Chen LL, Zhao Q, Yu YZ, Ding JJ et al (2014) Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases. Antimicrob Agents Chemother 58(1):511\u2013517. https:\/\/doi.org\/10.1128\/aac.02067-13","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-024-00743-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-024-00743-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-024-00743-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T06:07:26Z","timestamp":1727330846000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-024-00743-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["743"],"URL":"https:\/\/doi.org\/10.1007\/s00408-024-00743-w","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"1 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval was granted by the Yorkshire & The Humber\u2014Sheffield Research Ethics Committee (19\/YH\/0100).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all study participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}}]}}